Cancer Biomarkers Market Share, Opportunities, Demand, Top Players, Industry Insights and Future Growth Forecast 2021-2026

(The Express Wire via Comtex)

The global “Cancer Biomarkers Market Size” is forecast to reach USD 48.20 billion by 2026 on account of the increasing popularity of personalized treatment for cancer worldwide. Biomarkers help to detect cancer at an early stage and facilitate noninvasive diagnosis at high-speed by utilizing different proteomic and genomic markers. As per a recently published report by Fortune Business insights™ titled, “Cancer Biomarkers Market Size, Share and Industry Analysis, By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer And Others), By Biomarker Type (PSA, HER-2, EGFR, KRAS, and others), By End User (Pharmaceutical and Biotechnology Companies, Diagnostics and Research Laboratories, Hospitals and Specialty Clinics, and Others), and Regional Forecast, 2019-2026,” the market size was USD 18.94 billion in 2018 and will exhibit a CAGR of 12.4% between 2019 and 2026.

The report covers:

  • Global Cancer Biomarkers Market trends, with detailed analysis on consumer trends and manufacturer trends.
  • Overview on supply analysis covering trends across raw material suppliers, technology providers and distributors.
  • Key areas of investments identifying market opportunities and challenges in forecast timeframe.
  • Competitive analysis of the industry players along with the overview on strategic management.
  • Comprehensive company profiles of the major industry players.

Request a Sample Copy of the Research Report:

Market Drivers

Rise in Prevalence of Cancer Worldwide to Augment Growth

The increasing prevalence of cancer is a prime factor boosting the cancer biomarkers market growth. In addition to this, the market is also witnessing a significant rise on account of the growing demand for drug discovery and development for various cancer types. Additionally, many pharmaceutical companies are investing massive amounts into research and development of novel biomarkers for cancer therapeutics. Moreover, many clinical trials and pipeline studies are currently heading towards the end stages of development, and their market entry is likely to attract high cancer biomarkers market revenue in the coming years.

On the flip side, the market may face challenges in terms of reimbursement policies supported by the governments. This is further attributed to the high cost of treatment for cancer, especially in developing nations. Nevertheless, government support in spreading awareness about cancer, and the availability of treatment options for the same are likely to create lucrative growth opportunities for the market in the forthcoming years.

For more information in the analysis of this report, visit:

Leading Players operating in the Cancer Biomarkers Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

  • Myriad RBM
  • Abbott
  • Hoffmann-La Roche Ltd.
  • BioVision Inc.
  • Thermo Fisher Scientific
  • RandD System
  • Bio-Rad Laboratories, Inc.
  • Sino Biological Inc.
  • Sino Biological Inc.
  • Axon Medchem

Regional Segmentation:

North America to Emerge Dominant Owing to Higher Adoption of Next-Generation Sequencing

From a geographical perspective, the global cancer biomarker market is widespread into the regions of North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Each of these regions is further categorized into nations. Among these, North America earned USD 6.88 billion in 2018 and emerged dominant owing to the high adoption personalized medicine. Europe ranks second in the market with a rising number of research studies for using biomarkers in development and discovery.

Furthermore, the market in the Asia Pacific is expected to contribute significant oncology biomarker market share on account of rising in investments for research and development of biomarkers. This, coupled with increasing support from government and private bodies for the drug development process and patient stratification.

Detailed Table of Content:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Prevalence/ Incidence, by Cancer Type, by Key Regional/ Countries
    • New Product Launches, by Key Market Players
    • Pipeline Analysis, Cancer Biomarkers
    • Key industry Developments - Mergers, Acquisitions and Partnerships
  • Global Cancer Biomarkers Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast By Cancer Type
      • Lung Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Prostate Cancer
      • Others
    • Market Analysis, Insights and Forecast By Biomarker Type
      • PSA
      • HER-2
      • EGFR
      • KRAS
      • Others
    • Market Analysis, Insights and Forecast By End User
      • Pharmaceutical and Biotechnology Companies
      • Diagnostics and Research Laboratories
      • Hospitals and Specialty Clinics
      • Others
    • Market Analysis, Insights and Forecast By Region
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East and Africa

Have Any Query? Ask Our Experts:

Report Focus:

  • Extensive product offerings
  • Customer research services
  • Robust research methodology
  • Comprehensive reports
  • Latest technological developments
  • Value chain analysis
  • Potential Cancer Biomarkers Market opportunities
  • Growth dynamics
  • Quality assurance
  • Post-sales support
  • Regular report updates

Reasons to Purchase this Report:

  • Comprehensive analysis of the Cancer Biomarkers Market growth drivers, obstacles, opportunities, and other related challenges.
  • Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
  • Identifies market restraints and boosters.
  • Identifies all the possible segments present in the market to aid organizations in strategic business planning.

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.


US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email:[email protected]


Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Cancer Biomarkers Market Share, Opportunities, Demand, Top Players, Industry Insights and Future Growth Forecast 2021-2026

comtex tracking